Patents by Inventor Siegfried Bialojan

Siegfried Bialojan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrimidine compounds and the use thereof
    Patent number: 6444674
    Abstract: The present invention relates to the use of pyrimidine compounds of the following formula: where R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: September 3, 2002
    Assignee: Abbott Laboratories
    Inventors: Beate Hellendahl, Annegret Lansky, Rainer Munschauer, Siegfried Bialojan, Liliane Unger, Hans-Jürgen Teschendorf, Karsten Wicke, Karla Drescher
  • Triazole compounds and the use thereof
    Patent number: 6403593
    Abstract: The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: June 11, 2002
    Assignee: Abbott Laboratories
    Inventors: Beate Hellendahl, Annegret Lansky, Rainer Munschauer, Siegfried Bialojan, Liliane Unger, Hans-Jürgen Teschendorf, Karsten Wicke, Karla Drescher
  • Substitute pyrimidine compounds and the use thereof
    Patent number: 6342604
    Abstract: The present invention relates to the use of pyrimidine compounds of the following formula: wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: January 29, 2002
    Assignee: BASF Aktiengesellschaft
    Inventors: Beate Hellendahl, Annegret Lansky, Rainer Munschauer, Siegfried Bialojan, Liliane Unger, Hans-Jürgen Teschendorf, Karsten Wicke, Karla Drescher
  • Triazole compounds and the use thereof
    Patent number: 6124294
    Abstract: The present invention relates to triazole compounds of the following formula: where R.sup.1, R.sup.2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D.sub.3 ligands.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: September 26, 2000
    Assignee: BASF Aktiengesellschaft
    Inventors: Beate Hellendahl, Annegret Lansky, Rainer Munschauer, Siegfried Bialojan, Liliane Unger, Hans-Jurgen Teschendorf, Karsten Wicke, Karla Drescher
  • Use of carboxylic acid derivatives as drugs
    Patent number: 5840722
    Abstract: A method of inhibiting endothelin receptors by administering to a patient a compound of the formula I ##STR1##
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: November 24, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: Ernst Baumann, Uwe Josef Vogelbacher, Joachim Rheinheimer, Dagmar Klinge, Hartmut Riechers, Burkhard Kroger, Siegfried Bialojan, Claus Bollschweiler, Wolfgang Wernet, Liliane Unger, Manfred Raschack
  • Thrombin-inhibitory protein from ticks
    Patent number: 5827731
    Abstract: A novel thrombin-inhibitory protein from ticks with a molecular weight of about 8000 Dalton and the N terminus Leu-Asn-Val-Leu-Cys-Asn-Asn-Pro-His-Thr-Ala-Asp-Cys-Asn-Asn-Asp-Ala-Gln-Va l-Asp is described. The protein is suitable for controlling diseases.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: October 27, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: Thomas Friedrich, Siegfried Bialojan, Claus Bollschweiler, Christoph Kuenast
  • Recombinant fibrinogenases, the preparation and use thereof
    Patent number: 5759541
    Abstract: Novel polypeptides having fibrinogenolytic properties and having amino acid sequences as SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 indicated in the Sequence Listing, the preparation and use thereof for controlling diseases.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: June 2, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: Alfred Bach, Heinz Hillen, Siegfried Bialojan
  • Thrombin-inhibitory protein from ticks
    Patent number: 5585350
    Abstract: A novel thrombin inhibitory protein from ticks with a molecular weight of about 26000 dalton and the partial amino acid sequences Val-Ala-Lys-Phe-Ala-X-Asn-Ser-Gly-Ser-Glu-Thr-Gly (SEQ ID NO: 8), His-Ala-Y-Phe-Glu (SEQ ID NO: 3), Arg-Val-Ser-Asp-Phe-Glu (SEQ ID NO: 4), Phe-Val-Tyr-Thr-Ile-Glu (SEQ ID NO: 6), where X and Y can be identical or different and each is a naturally occurring amino acid, is suitable for controlling diseases.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: December 17, 1996
    Assignee: BASF Aktiengesellschaft
    Inventors: Thomas Friedrich, Wolfgang Koerwer, Burkhard Kroeger, Siegfried Bialojan
  • Thrombin-inhibitory protein from assassin bugs
    Patent number: 5523287
    Abstract: A novel thrombin-inhibitory protein from assassin bugs with a molecular weight of about 12,000 dalton and the N terminus Glu-Gly-Gly-Glu-Pro-Cys-Ala-Cys-Pro-His-Ala-Leu-His-Arg-Val-Cys-Gly-Ser-As p is described. The protein is suitable for controlling diseases.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: June 4, 1996
    Assignee: BASF Aktiengesellschaft
    Inventors: Thomas Friedrich, Siegfried Bialojan, Burkhard Kroeger, Christoph Kuenast
  • Thrombin-inhibitory proteins from terrestrial leeches
    Patent number: 5455181
    Abstract: Novel thrombin-inhibitory proteins from terrestrial leeches of the genus Haemadipsa with the amino-acid sequence Ile-Arg-Phe-Gly-Met-Gly-Lys-Val-Pro-Cys-Pro-Asp-Gly-Glu-Val-Gly-Tyr-Thr-Cy s-Asp-Cys-Gly-Glu-Lys-Ile-Cys-Leu-Tyr-Gly-Gln-Ser-Cys-Asn-Asp-Gly-Gln-Cys-S er-Gly-Asp-Pro-Lys-Pro-Ser-Ser-Glu-Phe-Glu-Glu-Phe-Glu-Ile-Asp-Glu-Glu-Glu- Lys, or an amino-acid sequence which is obtained by C-terminal truncation of this sequence by from one to twelve amino acids, are described. The proteins are suitable for controlling diseases. Also described are the nucleic acids coding for these proteins.
    Type: Grant
    Filed: May 18, 1994
    Date of Patent: October 3, 1995
    Assignee: BASF Aktiengesellschaft
    Inventors: Karl-Hermann Strube, Siegfried Bialojan, Burkhard Kroeger, Thomas Friedrich